
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
Pharmaceutical Technology Europe
Click the title above to open the Pharmaceutical Technology Europe June 2014 issue in an interactive PDF format.






